Try our Advanced Search for more refined results
Life Sciences
-
January 28, 2026
ArentFox Schiff Launches Longevity Industry Group
ArentFox Schiff LLP on Wednesday announced the launch of a group geared toward advising companies focused on advancing wellness, preventive health care and the longevity of life.
-
January 28, 2026
LegitScript's Counterclaims Against PharmacyChecker Tossed
An Oregon federal court dismissed LegitScript's counterclaims accusing PharmacyChecker.com of making false statements about the legality of importing prescription drugs, in a suit accusing the pharmacy accreditation provider of blacklisting the price-checking website.
-
January 28, 2026
Robins Kaplan Takes Aim At Benicar MDL Fees Suit In NJ
Robins Kaplan LLP told a New Jersey federal court Wednesday that a suit over fees the firm collected in multidistrict litigation over blood pressure medication should be thrown out, saying it "parrot[s]" claims from earlier suits that were already dismissed.
-
January 28, 2026
Generics Makers Want Hospital Drug Data In Price-Fixing MDL
A group of 150 hospitals suing generic-drug makers for alleged price fixing in multidistrict litigation should hand over data on their drug purchases, the drugmakers have told a Pennsylvania federal court, arguing they don't sell directly to the hospitals and therefore have no records themselves.
-
January 28, 2026
3rd Circ. Appears Skeptical Of Quest's Early Win In 401(k) Suit
The Third Circuit on Wednesday pressed attorneys defending Quest Diagnostics Inc.'s pretrial defeat of a proposed class action from workers who alleged that their 401(k) savings were drained by underperforming investment funds, spotlighting the parties' disagreement over whether the lab company followed its own investment policy statement.
-
January 27, 2026
Ohio PBM Suit Belongs In Federal Court, 6th Circ. Rules
The Sixth Circuit on Tuesday ruled that Ohio's lawsuit accusing pharmacy benefit managers of driving up prescription prices through rebate schemes belongs in federal court, saying in an opinion recommended for publication that the suit imposes liability on conduct undertaken at the direction of a federal officer.
-
January 27, 2026
Lasik Provider Can't Shake Wiretap Claims In Tracking Row
The operator of a laser eye surgery website must face a proposed class action alleging it illegally shared patients' confidential medical information with Meta, a California federal judge ruled, finding that the plaintiff could continue to press allegations under state and federal wiretap law.
-
January 27, 2026
BioXcel Says Doctor Sent Fake Email About Alzheimer's Trial
Artificial intelligence-driven drugmaker BioXcel Therapeutics Inc. claimed a doctor in charge of a clinical trial site in Florida tried to cover up a failure to report an adverse event by submitting a fraudulent email to a federal inspector, according to a suit filed in Florida state court.
-
January 27, 2026
Kelley Drye Adds Ex-23andMe, Facebook Privacy Pros
Kelley Drye & Warren LLP said Monday it is boosting its privacy and information security practice with the addition of a former 23andMe attorney in California and a former Facebook attorney in Texas.
-
January 27, 2026
Medtronic Rival's VP Says Docs Praised Device But Didn't Buy
A vice president in charge of sales at Applied Medical testified Tuesday in a California federal trial over his company's antitrust claims against Medtronic, and said the overwhelmingly positive feedback Applied received from surgeons who used its advanced bipolar devices often didn't result in sales.
-
February 12, 2026
Law360 Seeks Members For Its 2026 Editorial Boards
Law360 is looking for avid readers of our publications to serve as members of our 2026 editorial advisory boards.
-
January 27, 2026
Biotech Fundraising A Good Sign For Public Markets
At the start of what many healthcare attorneys hope will be a busy year, public biotechs are raising cash, signaling a thawing public market and potentially fertile ground for IPOs.
-
January 27, 2026
CBP's Medical Care Oversight Needs Improvement, GAO Says
A report issued by the U.S. Government Accountability Office found that U.S. Customs and Border Protection sometimes failed to provide proper medical oversight for certain people in its custody, violating its own policies and guidance for medical care.
-
January 27, 2026
White House Pushed To Back PTAB Rule Change Proposal
Two groups representing inventors and startups have thrown their support behind the U.S. Patent and Trademark Office's proposal to limit America Invents Act patent reviews, saying it will give patent owners certainty and also protect against foreign challenges to domestic patents.
-
January 27, 2026
Investors Say Teva Can't Get Early Win In Price-Fixing Suit
Investors guided by Highfields Capital told a Connecticut federal court that Teva Pharmaceuticals can't escape their claims that its alleged collusion with other drugmakers to artificially inflate the price of generic drugs also inflated stock prices, reasoning that Teva executives falsely attributed the company's performance to factors other than the alleged price-fixing.
-
January 27, 2026
Mylan's Sanofi Insulin Suit Mostly Survives Dismissal Bid
A Pennsylvania federal judge Tuesday largely refused to dismiss Mylan Pharmaceuticals' antitrust lawsuit accusing Sanofi of unlawfully maintaining a monopoly in the market for injectable insulin glargine.
-
January 26, 2026
Generics Makers Fight Cert. In Cholesterol Drug Pricing MDL
Generic-drug makers sought to defeat a bid to certify proposed classes comprising thousands of pharmacies that indirectly purchased and resold generics at the center of sprawling price-fixing litigation, telling a Pennsylvania federal court Monday that certification would result in an "unmanageable trial."
-
January 26, 2026
Masimo Chafes Against Apple's Bid To Duck $634M IP Verdict
Masimo has urged a California federal court to turn down Apple's request for relief from its $634 million trial loss in the companies' patent infringement fight over the Apple Watch, arguing that the company has made "extraordinarily untimely" attempts to change the meaning of "patient monitor."
-
January 26, 2026
Ill. Judge Trims False Ad Suit Over Abbott Formula
An Illinois federal judge Friday dismissed several claims in a putative class action alleging Abbott Laboratories falsely advertised its toddler drinks sold under the Similac brand as nutritionally proper for children ages 12 months to 36 months, but largely allowed the parents' complaint to move forward.
-
January 26, 2026
Novo Nordisk Faces Class Claims Over GLP-1 Patent Tactics
A South Carolina drug company has launched a proposed class action against major pharmaceutical company Novo Nordisk, alleging it engaged in anticompetitive behavior to prolong its monopoly against generic competition for the GLP-1 drug Victoza.
-
January 26, 2026
O'Melveny Brings On Proskauer M&A Pro In California
O'Melveny & Myers LLP announced Monday that it added a corporate dealmaker to its Newport Beach, California, office from the Los Angeles office of Proskauer Rose LLP.
-
January 26, 2026
Zenas BioPharma Slams Investor's Revamped Fraud Claim
Zenas BioPharma has asked a Massachusetts federal judge to toss a putative investor class action targeting pre-initial public offering statements about the company's spending, saying it didn't hide that it had ramped up investment in research and development.
-
January 26, 2026
Catching Up With Delaware's Chancery Court
The Delaware Chancery Court wrapped up the week with a slate of high-stakes deal challenges, governance rulings and oversight decisions, including an emergency bid to block a $10.9 billion bank merger, a state Supreme Court reversal reshaping stockholder agreement litigation and a major opinion allowing sexual misconduct oversight claims to proceed.
-
January 23, 2026
DC Circ. Revives Terrorism Liability Suit Against Pharma Cos.
A D.C. Circuit panel revived a lawsuit Friday accusing pharmaceutical companies of aiding a Hezbollah-linked militia's terrorism in Iraq, saying the victims behind the case have adequately alleged that the companies' participation was conscious and voluntary.
-
January 23, 2026
Paraquat, J&J Talc Litigation Headline Philly's 2026 Mass Torts
Cases concerning illnesses stemming from the herbicide paraquat and talcum power are kicking off 2026 in Philadelphia's mass tort system, pitting corporate powerhouses like Chevron, Syngenta and Johnson & Johnson against the city's perceived plaintiff-friendly juries.
Expert Analysis
-
Software Patents May Face New Eligibility Scrutiny
November guidance from the U.S. Patent and Trademark Office, along with recent litigation trends from the Federal Circuit, may encourage new challenges in the USPTO and district courts to artificial intelligence and software patents that rely on generic computing functions without concrete details, say attorneys at Venable.
-
Opinion
A Uniform Federal Rule Would Curb Gen AI Missteps In Court
To address the patchwork of courts’ standing orders on generative artificial intelligence, curbing abuses and relieving the burden on judges, the federal judiciary should consider amending its civil procedure rules to require litigants to certify they’ve reviewed legal filings for accuracy, say attorneys at Shook Hardy.
-
Riding The Changing Winds For AI Innovations At The USPTO
As recent U.S. Patent and Trademark Office moves reshape how artificial intelligence inventions will be examined and put them on firmer eligibility footing, practitioners need to consider how this shift is both an opportunity and a challenge, say Ryan Phelan at Marshall Gerstein and attorney Mark Campagna.
-
Series
The Law Firm Merger Diaries: Integrating Practice Groups
Enacting unified leadership and consistent client service standards ensures law firm practice groups connect and collaborate around shared goals, turning a law firm merger into a platform for growth rather than a period of disruption, says Brian Catlett at Fennemore Craig.
-
Opinion
Supreme Court Term Limits Would Carry Hidden Risk
While proposals for limiting the terms of U.S. Supreme Court justices are popular, a steady stream of relatively young, highly marketable ex-justices with unique knowledge and influence entering the marketplace of law and politics could create new problems, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.
-
Next Steps For Orgs. Amid Updated OpenAI Usage Policies
OpenAI's updates to its usage policies, clarifying that its tools are not substitutes for professional medical, legal or other regulated advice, sends a clear signal that organizations should mirror this clarity in their governance policies to mitigate compliance and liability exposure, say attorneys at Baker Donelson.
-
Series
Knitting Makes Me A Better Lawyer
Stretching my skills as a knitter makes me a better antitrust attorney by challenging me to recalibrate after wrong turns, not rush outcomes, and trust that I can teach myself the skills to tackle new and difficult projects — even when I don’t have a pattern to work from, says Kara Kuritz at V&E.
-
How 11th Circ.'s Qui Tam Review Could Affect FCA Litigation
On Dec. 12, the Eleventh Circuit will hear arguments in U.S. ex rel. Zafirov v. Florida Medical Associates, setting the stage for a decision that could drastically reduce enforcement under the False Claims Act, and presenting an opportunity to seek U.S. Supreme Court review of the act's whistleblower provisions, say attorneys at Epstein Becker.
-
Series
The Biz Court Digest: Welcome To Miami
After nearly 20 years in operation, the Miami Complex Business Litigation Division is a pioneer upon which other jurisdictions in the state have been modeled, adopting many innovations to keep its cases running more efficiently and staffing experienced judges who are accustomed to hearing business disputes, say attorneys at King & Spalding.
-
Identifying And Resolving Conflicts Among Class Members
As the Fifth Circuit's recent decision in Nova Scotia Health Employees' Pension Plan v. McDermott International illustrates, intraclass conflicts can determine the fate of a class action — and such conflicts can be surprisingly difficult to identify, says Andrew Faisman, a clerk at the U.S. District Court for the Southern District of New York.
-
Adapting To A Plaintiff-Side Mindset For Patent Monetization
A recent decrease in risk for patent owners at the U.S. Patent and Trademark Office, combined with increased corporate interest in monetizing patent assets, creates an attractive case for evaluating patents from a plaintiff-side mindset, but in-house counsel transitioning from a defense-side mindset to a plaintiff-side mindset should study certain considerations, says Kate Tellez at Steptoe.
-
AI Evidence Rule Tweaks Encourage Judicial Guardrails
Recent additions to a committee note on proposed Rule of Evidence 707 — governing evidence generated by artificial intelligence — seek to mitigate potential dangers that may arise once machine outputs are introduced at trial, encouraging judges to perform critical gatekeeping functions, say attorneys at Lankler Siffert & Wohl.
-
Series
The Law Firm Merger Diaries: Getting The Message Across
Communications and brand strategy during a law firm merger represent a crucial thread that runs through every stage of a combination and should include clear messaging, leverage modern marketing tools and embrace the chance to evolve, says Ashley Horne at Womble Bond.
-
Opinion
Horizontal Stare Decisis Should Not Be Casually Discarded
Eliminating the so-called law of the circuit doctrine — as recently proposed by a Fifth Circuit judge, echoing Justice Neil Gorsuch’s concurrence in Loper Bright — would undermine public confidence in the judiciary’s independence and create costly uncertainty for litigants, says Lawrence Bluestone at Genova Burns.
-
10 Commandments For Agentic AI Tools In The Legal Industry
Though agentic artificial intelligence has demonstrated significant promise for optimizing legal work, it presents numerous risks, so specific ethical obligations should be built into the knowledge base of every agentic AI tool used in the legal industry, says Steven Cordero at Akerman LLP.